Investors focused on the Medical space have likely heard of Fibrocell Science , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Fibrocell Science is a member of the Medical sector. This group includes 844 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. FCSC is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for FCSC's full-year earnings has moved 57.09% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that FCSC has returned about 42% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 3.81% on a year-to-date basis. This means that Fibrocell Science is performing better than its sector in terms of year-to-date returns.
Breaking things down more, FCSC is a member of the Medical - Biomedical and Genetics industry, which includes 352 individual companies and currently sits at #78 in the Zacks Industry Rank. Stocks in this group have gained about 3.54% so far this year, so FCSC is performing better this group in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on FCSC as it attempts to continue its solid performance.